SERSTECH AB: Serstech launches several new products and enters the pharmaceutical market
02 sept. 2019 03h15 HE
|
SERSTECH AB
Serstech today launches new versions of the Serstech 100 Indicator and the ChemDash software, both of which target the pharmaceutical and life-science market. The instrument and software are compliant...
AVRA Medical Robotics Initiates Food and Drug Administration Approval Process
28 août 2019 10h09 HE
|
AVRA Medical Robotics, Inc.
ORLANDO, Fla., Aug. 28, 2019 (GLOBE NEWSWIRE) -- AVRA Medical Robotics, Inc. (the “Company”) (OTCQB: AVMR), an emerging growth company that is in the process of building a fully autonomous medical...
CO Gov Polis charts course for CBD and hemp innovation at sold-out AHPA Supplement Congress
22 août 2019 10h11 HE
|
American Herbal Products Association (AHPA)
Denver, CO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Colorado Governor Jared Polis rallied more than 200 hemp farmers, manufacturers, producers, retailers, and industry professionals during his keynote...
Plus Therapeutics Reports Q2 2019 Financial and Business Results
15 août 2019 19h21 HE
|
Plus Therapeutics, Inc.
AUSTIN, Texas, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced Q2 2019 financial results and provided updates on corporate activities. Q2...
Syapse Announces Research Collaboration with the FDA Focused on the Regulatory Use of Real-World Evidence
14 août 2019 06h00 HE
|
Syapse
SAN FRANCISCO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement...
American Premium Water Corp (OTC:HIPH) Positions Itself for Opportunities in CBD Sector in Advance of FDA Guidance on CBD
01 août 2019 08h30 HE
|
American Premium Water Co.
PLAYA VISTA, CA, Aug. 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American Premium Water Corporation (OTC: HIPH) (“the Company”) announces that as the Food and Drug Administration (FDA)...
Yhdysvaltain lääkeviranomainen FDA on myöntänyt myyntiluvan darolutamidille, joka on uusi lääke etäpesäkkeettömän, kastraatioresistentin eturauhassyövän (nmCRPC) hoitoon
31 juil. 2019 00h30 HE
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 31.7.2019 klo 7.30 Yhdysvaltain lääkeviranomainen FDA on myöntänyt myyntiluvan darolutamidille, joka on uusi lääke etäpesäkkeettömän,...
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)
31 juil. 2019 00h30 HE
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 31 JULY 2019 at 7.30 EEST U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer...
Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA
25 juil. 2019 09h15 HE
|
Abeona Therapeutics Inc.
Neurocognitive development of youngest patients preserved 12-18 months post treatment; development scores remain within range of unaffected children Robust and sustained biomarker improvement across...
Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
25 juil. 2019 07h00 HE
|
Capricor Therapeutics, Inc.
--Independent Data Safety Monitoring Board recommends to continue HOPE-2 study-- --Capricor to resume treating currently enrolled patients-- LOS ANGELES, July 25, 2019 (GLOBE NEWSWIRE) -- Capricor...